Todd Fralich

466 total citations
11 papers, 340 citations indexed

About

Todd Fralich is a scholar working on Infectious Diseases, Virology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Todd Fralich has authored 11 papers receiving a total of 340 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Infectious Diseases, 9 papers in Virology and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Todd Fralich's work include HIV Research and Treatment (9 papers), HIV/AIDS drug development and treatment (9 papers) and HIV/AIDS Research and Interventions (7 papers). Todd Fralich is often cited by papers focused on HIV Research and Treatment (9 papers), HIV/AIDS drug development and treatment (9 papers) and HIV/AIDS Research and Interventions (7 papers). Todd Fralich collaborates with scholars based in United States, Germany and United Kingdom. Todd Fralich's co-authors include Kirsten White, Danielle Porter, Ramin Ebrahimi, Jan van Lunzen, Shampa De-Oertel, José Ramón Arribas, Keith Henry, Pablo Tebas, Martin Fisher and Frank J. Palella and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Clinical Infectious Diseases.

In The Last Decade

Todd Fralich

11 papers receiving 334 citations

Peers

Countries citing papers authored by Todd Fralich

Since Specialization

Citations

This map shows the geographic impact of Todd Fralich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Todd Fralich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Todd Fralich more than expected).

Fields of papers citing papers by Todd Fralich

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Todd Fralich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Todd Fralich. The network helps show where Todd Fralich may publish in the future.

Co-authorship network of co-authors of Todd Fralich

This figure shows the co-authorship network connecting the top 25 collaborators of Todd Fralich. A scholar is included among the top collaborators of Todd Fralich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Todd Fralich. Todd Fralich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study 2024 ·European Urology ·Fred Saad, Maha Hussain, Bertrand Tombal, Karim Fizazi, Cora N. Sternberg, E. David Crawford, Luke T. Nordquist, Martin Bögemann, Ronald Tutrone, Neal D. Shore, Laurence Belkoff, Todd Fralich, Jay Jhaveri, Shankar Srinivasan, Rui Li, Frank Verholen, Iris Kuss, Matthew R. Smith	18
2	Overall survival with darolutamide vs placebo in combination with androgen-deprivation therapy (ADT) and docetaxel: A sensitivity analysis from ARASENS accounting for subsequent therapy. 2024 ·Journal of Clinical Oncology ·Neal D. Shore, Bertrand Tombal, Maha Hussain, Fred Saad, Karim Fizazi, Cora N. Sternberg, E. David Crawford, Todd Fralich, Rui Li, Matthew R. Smith	1
3	96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects 2015 ·HIV Clinical Trials ·Danielle Porter, Rima Kulkarni, Todd Fralich, Michael D. Miller, Kirsten White	12
4	Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults 2014 ·AIDS ·Calvin Cohen, David A. Wohl, José Ramón Arribas, Keith Henry, Jan van Lunzen, Mark Bloch, (unknown), Edmund Wilkins, Ramin Ebrahimi, Danielle Porter, Kirsten White, (unknown), Susan K. Chuck, Shampa De-Oertel, Todd Fralich	86
5	Fanconi Syndrome Accompanied by Renal Function Decline with Tenofovir Disoproxil Fumarate: A Prospective, Case-Control Study of Predictors and Resolution in HIV-Infected Patients 2014 ·PLoS ONE ·Samir K. Gupta, Albert M. Anderson, Ramin Ebrahimi, Todd Fralich, Hiba Graham, (unknown), John F. Flaherty, Claude Fortin, Robert C. Kalayjian, Anita Rachlis, Christina Wyatt	37
6	Characterization of HIV-1 Drug Resistance Development Through Week 48 in Antiretroviral Naive Subjects on Rilpivirine/Emtricitabine/Tenofovir DF or Efavirenz/Emtricitabine/Tenofovir DF in the STaR Study (GS-US-264-0110) 2013 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Danielle Porter, Rima Kulkarni, Todd Fralich, Michael D. Miller, Kirsten White	20
7	Efficacy of switching to rilpivirine/emtricitabine/tenofovir DF from boosted PI in HIV-1 virologically suppressed patients with or without the K103N 2013 ·Journal of the International AIDS Society ·(unknown), Pablo Tebas, Martin Fisher, Brian Gazzard, (unknown), Jan van Lunzen, David Shamblaw, Jason Flamm, Ramin Ebrahimi, Danielle Porter, (unknown), Shampa De-Oertel, Todd Fralich, Romina Quercia	2
8	Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants 2013 ·AIDS ·Frank J. Palella, Martin Fisher, Pablo Tebas, Brian Gazzard, Peter Ruane, Jan van Lunzen, David Shamblaw, Jason Flamm, Ramin Ebrahimi, Danielle Porter, Kirsten White, Jason T. Hindman, (unknown), Shampa De-Oertel, Todd Fralich	92
9	SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen 2013 ·Clinical Infectious Diseases ·Rafael Campo, E DeJesus, U. Fritz Bredeek, Keith Henry, Homayoon Khanlou, (unknown), Cynthia Brinson, Paul Benson, (unknown), (unknown), Kirsten White, John F. Flaherty, Todd Fralich, Bill Guyer, David Piontkowsky	36
10	SPIRIT: switching to emtricitabine/rilpivirine/tenofovir DF single‐tablet regimen from boosted protease inhibitor maintains HIV suppression at week 48 2012 ·Journal of the International AIDS Society ·Martin Fisher, Frank J. Palella, Pablo Tebas, Brian Gazzard, (unknown), Jan van Lunzen, David Shamblaw, Jason Flamm, Ramin Ebrahimi, Kirsten White, (unknown), Danielle Porter, Todd Fralich	11
11	STAR Study: single tablet regimen emtricitabine/rilpivirine/tenofovir DF is non‐inferior to efavirenz/emtricitabine/tenofovir DF in ART‐naïve adults 2012 ·Journal of the International AIDS Society ·Cal Cohen, (unknown), José Ramón Arribas, Kenneth R. Henry, Jan van Lunzen, (unknown), William Towner, Ed Wilkins, (unknown), (unknown), Danielle Porter, Bill Guyer, Todd Fralich	25

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact